Glycosylation of prostate specific antigen and its potential diagnostic applications

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1500-1505

  Vermassen, Tijl ^a   Speeckaert, Marijn M ^a   Lumen, Nicolaas ^a   Rottey, Sylvie ^a   Delanghe, Joris R ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Benign prostatic hyperplasia; Glycosylation; Lectin; Prostate cancer; Prostate specific antigen isoforms

Indexed keywords

AGGLUTININ; ALEURIA AURANTIA AGGLUTININ; CONCANAVALIN A; LECTIN; LENS CULINARIS AGGLUTININ; MAACKIA AMURENSIS LECTIN I; PHASEOLUS VULGARIS LEUKOAGGLUTININ; PROSTATE SPECIFIC ANTIGEN; SAMBUCUS NIGRA AGGLUTININ; TRICHOSANTHES JAPONICA AGGLUTININ II; ULEX EUROPAEUS AGGLUTININ; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER DIAGNOSIS; CAPILLARY ELECTROPHORESIS; DIAGNOSTIC VALUE; HUMAN; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; REVIEW; SEMINAL PLASMA; SERUM; TUMOR CELL LINE; TWO DIMENSIONAL ELECTROPHORESIS; URINE;

CELL LINE, TUMOR; DIAGNOSIS, DIFFERENTIAL; ELECTROPHORESIS, CAPILLARY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GLYCOSYLATION; HUMANS; LECTINS; MALE; MASS SPECTROMETRY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; SEMEN;

EID: 84863093442     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.06.007     Document Type: Review

References (97)

1. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
2. Végvári A., Rezeli M., Sihlbom C., et al. Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry. Clin Biochem 2012, 45:331-338.
3. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
4. Lundwall Å., Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987, 214:317-322.
5. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., et al. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998, 35:275-368.
6. Lilja H., Christensoso A., Dahlen U., et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991, 37:1618-1625.
7. Ward A.M., Catto J.W., Hamdy F.C. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 2001, 38:633-651.
8. Bolduc S., Lacombe L., Naud A., et al. Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J 2007, 1:377-381.
9. Thiel R.P., Oesterling J.E., Wojno K.J., et al. Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology 1996, 48:S45-S50.
10. Christensson A., Björk T., Nilsson O., et al. Serumprostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993, 150:100-105.
11. Canto E.I., Singh H., Shariat S.F., Lamb D.J., et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004, 63:905-910.
12. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. "BPSA", a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000, 55:41-45.
13. Loeb S., Catalona W.J. What to do with an abnormal PSA test. Oncologist 2008, 13:299-305.
14. Nogueira L., Corradi R., Eastham J.A. Other biomarkers for detecting prostate cancer. BJU Int 2010, 105:166-169.
15. Dwek M.V., Brooks S.A. Harnessing changes in cellular glycosylation in new cancer treatment strategies. Curr Cancer Drug Targets 2004, 4:425-442.
16. Li Y., Tao S.C., Bova G.S., et al. Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. Anal Chem 2011, 83:8509-8516.
17. Huber P.R., Schmid H.P., Mattarelli G., et al. Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate. Prostate 1995, 27:212-219.
18. Peracaula R., Barrabés S., Sarrats A., et al. Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers 2008, 25:207-218.
19. Belanger A., van Halbeek H., Graves H.C., et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 1995, 27:187-197.
20. Lövgren J., Rajakoski K., Karp M., et al. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997, 238:549-555.
21. Takayama T.K., Fujikawa K., Davie E.W. Characterization of the precursor of prostate-specific antigen. J Biol Chem 1997, 272:21582-21588.
22. Emami N., Diamandis E.P. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. J Biol Chem 2008, 283:3031-3041.
23. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985, 76:1899-1903.
24. Lilja H., Oldbring J., Rannevik G., et al. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987, 80:281-285.
25. Pezzato E., Sartor L., Dell'Aica I., et al. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int J Cancer 2004, 112:787-792.
26. Watt K.W.K., Lee P.-J., M'Timkulu T., et al. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986, 83:3166-3170.
27. Emami N., Diamandis E.P. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. J Biol Chem 2008, 283:3031-3041.
28. Christensson A., Lilja H. Complex-formation between protein-C inhibitor and prostate-specific antigen in-vitro and in human semen. Eur J Biochem 1994, 220:45-53.
29. Espana F., Gilabert J., Estelles A., et al. Functionally active protein-C inhibitor plasminogen-activator inhibitor-3 (PCI/PAI-3) is secreted in seminal-vesicles, occurs at high-concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 1991, 64:309-320.
30. Laurell M., Christensson A., Abrahamsson P.A., et al. Protein-C inhibitor in human-body fluids-seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive-system. J Clin Invest 1992, 89:1094-1101.
31. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008, 8:268-278.
32. Okada T., Sato Y., Kobayashi N., et al. Structural characteristics of the N-glycans of two forms of prostate-specific antigens purified from human seminal fluid. Biochem Biophys Acta 2001, 1525:149-160.
33. Isono T., Tanaka T., Kageyama S., et al. Structural diversity of cancer-related and non-cancer-related prostate-specific antigen. Clin Chem 2002, 48:2187-2194.
34. Sarrats A., Comet J., Tabarés G., et al. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis. Prostate 2010, 70:1-9.
35. Chen S., LaRoche T., Hamelinck D., et al. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 2007, 4:437-444.
36. Zeng Z., Hincapie M., Pitteri S.J., et al. A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome. Anal Chem 2011, 83:4845-4854.
37. Feng S., Yang N., Pennathur S., et al. Enrichment of glycoproteins using nanoscale chelating concanavalin A monolithic capillary chromatography. Anal Chem 2009, 81:3776-3783.
38. McCoy J.P., Varani J., Goldstein I.J. Enzyme-linked lectin assay (ELLA): use of alkaline phosphatase-conjugated Griffonia simplicifolia B4 isolectin for the detection of alpha-d-galactopyranosyl end groups. Anal Biochem 1983, 130:437-444.
39. Gornik O., Lauc G. Enzyme linked lectin assay (ELLA) for direct analysis of transferrin sialylation in serum samples. Clin Biochem 2007, 40:718-723.
40. Knibbs R.N., Goldstein I.J., Ratcliffe R.M., et al. Characterization of the carbohydrate binding specificity of the leukoagglutinating lectin from Maackia amurensis. Comparison with other sialic acid-specific lectins. J Biol Chem 1991, 266:83-88.
41. Kawaguchi T., Matsumoto I., Osawa T. Studies on hemagglutinins from Maackia amurensis seeds. J Biol Chem 1974, 249:2786-2792.
42. Meany D., Zhang Z., Sokoll L., et al. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteom Res 2009, 8:613-619.
43. Chan D.W., Gao Y.M. Variants of prostate specific antigen separated by Concanavalin A. Clin Chem 1991, 37:1133-1134.
44. Marrink J., Klip H., de Jong R. Prostate-specific-antigen-con A binding ratio in benign prostate hyperplasia and prostate cancer. Lancet 1992, 339:619-620.
45. Pelt J., van Dieijen-Visser M.P. PSA-con A-binding ratio in benign prostate hyperplasia and prostate cancer. Lancet 1992, 340:174-175.
46. Barak M., Mecz Y., Lurie A., et al. Binding of serum prostate specific antigen to concanavalin A in patients with cancer or hyperplasia of the prostate. Oncology 1989, 46:375-377.
47. Basu P.S., Ramdhan M., Batabyal S.K. Lectin and serum-PSA interaction as a screening test for prostate cancer. Clin Biochem 2003, 36:373-376.
48. Batabyal S.K., Majhi R., Basu P.S. Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer. Neoplasma 2009, 56:68-71.
49. Dwek M.V., Jenks A., Leathem A.J. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin Chim Acta 2010, 411:1935-1939.
50. Saldova R., Fan Y., Fitzpatrick J.M., et al. Core fucosylation and α2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 2011, 21:195-205.
51. Fukushima K., Satoh T., Baba S., et al. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology 2010, 20:452-460.
52. Hammarström S., Hammarström M.L., Sundblad G., et al. Mitogenic leukoagglutinin from Phaseolus vulgaris binds to a pentasaccharide unit in N-acetyllactosamine-type glycoprotein glycans. Proc Natl Acad Sci U S A 1982, 79:1611-1615.
53. Lange T., Ullrich S., Muller I., et al. Human prostate cancer in a clinically relevant xenograft mouse model: identification of beta(1,6)-branched oligosaccharides as a marker of tumor progression. Clin Cancer Res 2012, 18:1364-1373.
54. Ohyama C., Hosono M., Nitta K., et al. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology 2004, 14:671-679.
55. Debray H., Decout D., Strecker G., et al. Specificity of twelve lectins towards oligosaccharides and glycopeptides related to N-glycosylproteins. Eur J Biochem 1981, 117:41-55.
56. Peracaula R., Tabarés G., Royle L., et al. Altered glycosylation pattern allows the distinction between prostate specific antigen (PSA) from normal and tumour origins. Glycobiology 2003, 13:457-470.
57. Tabarés G., Jung K., Reiche J., et al. Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples. Clin Biochem 2007, 40:343-350.
58. Wada Y., Azadi P., Costello C.E., et al. Comparison of the methods for profiling glycoprotein glycans-HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology 2007, 17:411-422.
59. Li Y., Tian Y., Rezai T., et al. Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem 2011, 83:240-245.
60. Nwosu C.C., Seipert R.R., Strum J.S., et al. Simultaneous and extensive site-specific N- and O-glycosylation analysis in protein mixtures. J Proteome Res 2011, 10:2612-2624.
61. de Leoz M.L., An H.J., Kronewitter S., et al. Glycomic approach for potential biomarkers on prostate cancer: profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers 2008, 25:243-258.
62. Zhang H., Li X.J., Martin D.B., et al. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003, 21:660-666.
63. Tian Y., Zhou Y., Elliott S., et al. Solid-phase extraction of N-linked glycopeptides. Nat Protoc 2007, 2:334-339.
64. Van Lenten L., Ashwell J.G. Studies on the chemical and enzymatic modification of glycoproteins. A general method for the tritiation of sialic acid-containing glycoproteins. Biol Chem 1971, 246:1889-1894.
65. Charrier J.P., Tournel C., Michel S., et al. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia. Electrophoresis 1999, 20:1075-1081.
66. Isono T., Tanaka T., Kageyama S., et al. Structural diversity of cancer-related and non-cancer-related prostate-specific antigen. Clin Chem 2002, 48:2187-2194.
67. Jung K., Reiche J., Boehme A., et al. Analysis of subforms of free prostatespecific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer. Clin Chem 2004, 50:2292-2301.
68. Sarrats A., Saldova R., Comet J., et al. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma. OMICS 2010, 14:465-474.
69. Tabarés G., Radcliffe C.M., Barrabés S., et al. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology 2006, 16:132-145.
70. Garrido-Medina R., Díez-Masa J.C., de Frutos M. CE methods for analysis of isoforms of prostate-specific antigen compatible with online derivatization for LIF detection. Electrophoresis 2011, 32:2036-2043.
71. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989, 52:257-331.
72. Durand G., Seta N. Protein glycosylation and diseases: blood and urinary oligosaccharides as markers for diagnosis and therapeutic monitoring. Clin Chem 2000, 46:795-805.
73. Prakash S., Robbins P.W. Glycotyping of prostate specific antigen. Glycobiology 2000, 10:173-176.
74. Janković M.M., Kosanović M.M. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns. Clin Biochem 2005, 38:58-65.
75. Batabyal S.K., Majhi R., Basu P.S. Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer. Neoplasma 2009, 56:68-71.
76. Holmes E.H., Ostrander G.K., Hakomori S. Biosynthesis of the sialyl-Lex determinant carried by type 2 chain glycosphingolipids (IV3Neu AcIII3FucnLc4, VI3NeuAcV3FucnLc6, and VI3NeuAcIII3V3Fuc2nLc6) in human lung carcinoma PC9 cells. J Biol Chem 1986, 261:3737-3743.
77. Arnold J.N., Saldova R., Hamid U.M., et al. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 2008, 8:3284-3293.
78. Pannek J., Rittenhouse H.G., Evans C.L., et al. Molecular forms of prostate specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology 1997, 50:715-721.
79. Kosanović M., Janković M. Molecular forms of human prostate-specific antigen in urine of subjects with benign prostatic hyperplasia. Arch Biol Sci Belgrade 2006, 58:77-82.
80. Sumi S., Arai K., Kitahara S., et al. Serial lectin affinity chromatography demonstrates altered asparagine-linked sugar chain structures of prostate-specific antigen in human prostate carcinoma. J Chromatogr B Biomed Sci Appl 1999, 727:9-14.
81. Tajiri M., Ohyama C., Wada Y. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. Glycobiology 2008, 18:2-8.
82. Samadi A.A., Davidson S.D., Mordente J.A., et al. Differential glycosylation of cellular prostate specific antigen and the regulatory mechanism of its secretion. Mol Urol 1999, 3:147-152.
83. Sumi S., Arai K., Yoshida K. Separation methods applicable to prostate cancer diagnosis and monitoring therapy. J Chromatogr B Biomed Sci Appl 2001, 764:445-455.
84. Debruyne E., Delanghe J. Diagnosing and monitoring hepatocellular carcinoma with alpha fetoprotein: new aspects and applications. Clin Chim Acta 2008, 395:19-26.
85. Kobata A., Endo T. Immobilized lectin columns: useful tools for the fractionation and structural analysis of oligosaccharides. J Chromatogr 1992, 597:111-122.
86. Delanghe J.R., Bollen M., Beullens M. Testing for recombinant erythropoietin. Am J Hematol 2008, 83:237-241.
87. Gornik O., Lauc G. Enzyme linked lectin assay (ELLA) for direct analysis of transferrin sialylation in serum samples. Clin Biochem 2007, 40:718-723.
88. McCoy J.P., Varani J., Goldstein I.J. Enzyme-linked lectin assay (ELLA): use of alkaline phosphatase-conjugated Griffonia simplicifolia B4 isolectin for the detection of alpha-d-galactopyranosyl end groups. Anal Biochem 1983, 130:437-444.
89. Mehta A.S., Long R.E., Comunale M.A., et al. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol 2008, 82:1259-1270.
90. Lotan R., Nicolson G.L. Purification of cell membrane glycoproteins by lectin affinity chromatography. Biochim Biophys Acta 1979, 559:329-376.
91. Davies C. Principles. The immunoassay handbook 1994, 3-47. Stockton Press, New York City. D. Wild (Ed.).
92. Drake P.M., Cho W., Li B., et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem 2010, 56:223-236.
93. Sughii S., Kabat E.A., Baer H.H. Further immunochemical studies on the combining sites of Lotus tetragonolobus and Ulex europaeus I and II lectins. Carbohydr Res 1982, 99:99-101.
94. Ravindranath M.H., Higa H.H., Cooper E.L., Paulson J.C. Purification and characterization of an O-acetylsialic acid-specific lectin from a marine crab Cancer antennarius. J Biol Chem 1985, 260:8850-8856.
95. Wang W.C., Cummings R.D. The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues. J Biol Chem 1988, 263:4576-4585.
96. Oliveira C., Teixeira J.A., Schmitt F., Domingues L. A comparative study of recombinant and native frutalin binding to human prostate tissues. BMC Biotechnol 2009, 9:78.
97. Kornfeld K., Reitman M.L., Kornfeld R. The carbohydrate-binding specificity of pea and lentil lectins. Fucose is an important determinant. J Biol Chem 1981, 256:6633-6640.